title: Stent-based antirestenotic coatings (sirolimus/paclitaxel).
authors.affiliation: Bristol Heart Institute, University of Bristol, Bristol, U.K. martin.oberhoff@bristol.ac.uk
authors.forename: Martin
authors.initials: M
authors.lastname: Oberhoff
authors.forename: Christian
authors.initials: C
authors.lastname: Herdeg
authors.forename: Andreas
authors.initials: A
authors.lastname: Baumbach
authors.forename: Karl R
authors.initials: KR
authors.lastname: Karsch
mesh_terms: D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000494:pharmacology; D002455:Cell Division / Q000187:drug effects; D002986:Clinical Trials as Topic; D020099:Coated Materials, Biocompatible; D023903:Coronary Restenosis / Q000209:etiology / Q000517:prevention & control*; D003864:Depression, Chemical; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000494:pharmacology; D015918:Infusion Pumps, Implantable; D009131:Muscle, Smooth, Vascular / Q000166:cytology; D017239:Paclitaxel / Q000008:administration & dosage* / Q000494:pharmacology; D020123:Sirolimus / Q000008:administration & dosage* / Q000494:pharmacology; D015607:Stents / Q000009:adverse effects
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D020099:Coated Materials, Biocompatible; D007166:Immunosuppressive Agents; D017239:Paclitaxel; D020123:Sirolimus